naftidrofuryl oxalate

naftidrofuryl oxalate

peripheral vasodilatory drug used to reduce intermittent claudication (in conjunction with lifestyle changes, e.g. no smoking)
Mentioned in ?
References in periodicals archive ?
Some studies have shown that the medication Naftidrofuryl oxalate can make a little improvement.
After noting that calcium oxalate monohydrate crystalluria was higher in elderly patients, we undertook a study to determine if oral treatment with naftidrofuryl oxalate, a drug frequently prescribed for elderly patients in France, was associated with crystalluria.
5 years) of whom 49 had been treated orally with naftidrofuryl oxalate at a mean dosage of 48 5 [+ or -] 120 mg/24 h.
During a search for a possible drug-induced cause, we noted that naftidrofuryl oxalate was frequently prescribed for older people.
In the present study, we explored the relationship between crystalluria in elderly subjects and oral treatment with naftidrofuryl oxalate.
Among these 251 subjects, 49 were being treated orally with naftidrofuryl oxalate at a mean dosage of 485 [+ or -] 120mg/24h, which corresponds to usual doses.
Association of crystalluria and the taking of naftidrofuryl oxalate
Taking of Crystalluria naftidrofuryl oxalate Present Absent Total
The mean dosage of naftidrofuryl oxalate was 485 [+ or -] 120mg/24h.
We wanted to know whether the crystalluria was linked to oral treatment with naftidrofuryl oxalate, a drug which enhances the urinary crystallization of calcium oxalate when administered intravenously [4, 7].
Several findings contribute to our understanding of the onset of calcium oxalate crystalluria, preponderantly whewellite, in our elderly subjects treated with naftidrofuryl oxalate.
Furthermore, in previous studies, we demonstrated that patients with peripheral vascular disease, treated intravenously with naftidrofuryl oxalate 800 mg/day for 10 days, had a substantial increase in oxalate concentrations in serum and 24-hour urine collections (a 4- to 8-fold increase) [7].